Royalty Report: Drugs, Autoimmune, Drug Discovery – Collection: 385688

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Drugs
  • Autoimmune
  • Drug Discovery
  • Surgical
  • Antibody
  • Disease
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 385688

License Grant
Licensor grants under the Licensor Technology, Collaboration Inventions, and all patents claiming Collaboration Inventions, a co-exclusive license, together with Licensor, to develop in accordance with the Development Plan and use Licensed Products in the Asthma Field with respect to U.S. Territory and the European Union, a co-exclusive license, together with Licensor, to import Licensed Products in the Asthma Field into the European Union for such Development purposes, an exclusive license to import, offer for sale and sell Licensed Products in the Asthma Field in the U.S. Territory, and an exclusive license to make Licensed Products in the Asthma Field in the Territory.

For Additional Licenses to Collaboration Inventions, Licensor grants, under the Collaboration Inventions and all patents claiming Collaboration Inventions a co-exclusive license to develop, make, use, import, offer for sale and sell products, other than Licensed Products or Excluded Products, containing antibodies that bind to IL-2R in the Asthma Field in the Territory; and a co-exclusive license to develop, make, use, import, offer for sale, and sell Licensed Products and other products containing antibodies that bind to IL-2R, other than Excluded Products, in Licensee’s Exclusive Field in the Territory.

For the Trademark License, Licensor grants the co-exclusive right and license, together with Licensor to use the Zenapax Trademark solely in connection with the development, use, marketing, promotion, and detailing of Licensed Products in the Asthma Field in the U.S. Territory, the co-exclusive right and license, together with Licensor, to use the Zenapax Trademark solely in connection with the development of Licensed Products in the Asthma Field with respect to the European Union, and the exclusive right and license to use the Zenapax Trademark solely in connection with the offer for sale and sale of Licensed Products in the Asthma Field in the U.S. Territory.

License Property
Licensor currently markets a humanized antibody against the interleukin-2 (IL-2) receptor Daclizumab, under the trademark Zenapax®.

Autoimmune Indications or Al means all indications that involve pathogenic consequences, including tissue injury, produced by autoantibodies or autoreactive T lymphocytes interacting with self epitopes, i.e., autoantigens. Autoimmune Indications shall include, without limitation, asthma, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, juvenile rheumatoid arthritis, polymytosis, Type I diabetes, sarcoidosis, Sjogrens syndrome, chronic active nonpathogenic hepatitis, non-infectious uveitis (Behcets), aplastic anemia, regional nonpathogenic enteritis (including ulcerative colitis, Crohns Disease and inflammatory bowel disease), Kawasakis disease, post-infectious encephalitis, multiple sclerosis, and tropic spastic paraparesis.

Oaclizumab means that certain humanized murine monoclonal antibody directed against the p55 component of IL-2R and given the generic name Daclizumab by the United States Adopted Names Council. Oaclizumab does not include fragments of such antibody or any antibodies having a different amino acid sequence from such antibody.

Licensed Product shall mean any pharmaceutical product having as an active ingredient Oaclizumab.

Zenapax Trademark means the trademark Zenapax®, and all trademark registrations and applications therefor, and all goodwill associated therewith.

Field of Use
Zenapax (daclizumab), a Phase II humanized monoclonal antibody for moderate to severe asthma.   “Asthma Field” means the treatment and/or prevention of asthma or other respiratory diseases.

The Exclusive Field means, with respect to Licensor, Licensors Exclusive Field and, with respect to Licensee, Licensees Exclusive Field.

Licensors Exclusive Field means the Transplant Indications, Notwithstanding the foregoing, upon the first to occur of the Reversion Effective Date or the Put Right Effective Date, the term Licensors Exclusive Field shall have no meaning.

Licensee’s Exclusive Field means the Autoimmune Indications, excluding the Asthma Field, Other Indications and, upon the first to occur of the Reversion Effective Date or the Put Right Effective Date, the Transplant Indications.

IPSCIO Record ID: 391426

License Grant
The Parties are entering into a worldwide collaboration for the joint development and commercialization of Daclizumab for the treatment of asthma and other respiratory diseases.

In the U.S. Territory
— For the Technology License, Licensor grants a co-exclusive license, together with Licensor, under the Licensor Technology, to develop Licensed Products in the Asthma Field with respect to the U.S. Territory and the European Union, in accordance with the Development Plan, and to import and use Licensed Products for such purposes.  The foregoing licenses include the right to perform Development outside the U.S. Territory and European Union in accordance with the Development Plan with respect to any Licensed Product solely in order to obtain Regulatory Approval of such Licensed Product in the Asthma Field in the U.S. Territory or the European Union.
—  Promotion Right, Licensor grants a co-exclusive, together with Licensor, non-transferable right to Promote and Detail Licensed Products in the Asthma Field in the U.S. Territory during the Co-Promotion Term, in accordance with applicable law and the Commercialization Plan.

In the ROW Territory
— For the Technology License, Licensor grants the exclusive, even as to Licensor, license, under the Licensor Technology, to develop Licensed Products in the Asthma Field in the ROW Territory, other than the European Union, to use and import Licensed Products in the Asthma Field in the ROW Territory, other than the European Union, for such Development purposes, offer for sale and sell Licensed Products in the Asthma Field in the ROW Territory, to use and import Licensed Products in the Asthma Field in the ROW Territory for such commercialization purposes; provided, however, that the license granted with respect to the Queen Patents shall be nonexclusive.

For the Trademark License, Licensor grants the exclusive right and license to use the Licensor Trademarks solely in connection with the development, use, marketing, promotion, detailing, offer for sale and sale of Licensed Products in the Asthma Field in the ROW Territory; provided, however, that Licensee’s license shall be co-exclusive, together with Licensor, with respect to Development in the European Union.

For the Commercialization by Licensee in ROW Territory, except as expressly set forth, Licensee shall have sole responsibility and decision-making authority for the marketing, promotion, sale and distribution of the Licensed Product in the Asthma Field in the ROW Territory.

License Property
Licensor has acquired all rights to Zenapax, excluding transplantation indications but with the option to gain such indication rights by 2007.

Licensor Technology includes ownership of the Licensor Inventions, Know-How and Patents.

Licensed Product shall mean any pharmaceutical product having as an active ingredient Daclizumab.

Collaboration Inventions means all inventions that relate to or are useful with antibodies that bind the IL-2 receptor (IL-2R) and are made during the term of this Agreement by employees of Licensee or persons contractually required to assign or license patent rights covering such inventions to Licensee, in the course of performing Licensee’s obligations, or exercising Roche’s rights, under this Agreement.

Autoimmune Indications or Al means all indications that involve pathogenic consequences, including tissue injury, produced by autoantibodies or autoreactive T lymphocytes interacting with self epitopes, i.e., autoantigens. Autoimmune Indications shall include, without limitation, asthma, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, juvenile rheumatoid arthritis, polymytosis, Type I diabetes, sarcoidosis, Sjogrens syndrome, chronic active nonpathogenic hepatitis, non-infectious uveitis (Behcets), aplastic anemia, regional nonpathogenic enteritis (including ulcerative colitis, Crohns Disease and inflammatory bowel disease), Kawasakis disease, post-infectious encephalitis, multiple sclerosis, and tropic spastic paraparesis.

Daclizumab means that certain humanized murine monoclonal antibody directed against the p55 component of IL-2R and given the generic name Daclizumab by the United States Adopted Names Council. Daclizumab does not include fragments of such antibody or any antibodies having a different amino acid sequence from such antibody.

Zenapax Trademark means the trademark Zenapax®, and all trademark registrations and applications therefor, and all goodwill associated therewith.

Field of Use
The Exclusive Field means, with respect to Licensee, Licensees Exclusive Field and, with respect to Licensee, Licensees Exclusive Field.

Licensors Exclusive Field means the Autoimmune Indications, excluding the Asthma Field.

Licensees Exclusive Field means the Transplant Indications.

IPSCIO Record ID: 279338

License Grant
The Swiss Licensor hereby grants to Licensee, under the Licensor Technology, Licensor Inventions, and all patents claiming Licensor Inventions, (i) a co-exclusive license (together with Licensor) to develop in accordance with the Asthma Development Plan and Transplant Development Plan and use Licensed Products in the Collaborative Fields with respect to U.S. Territory and the European Union, (ii) a co-exclusive license (together with Licensor) to import Licensed Products in the Collaborative Fields into the European Union for such Development purposes, (iii) an exclusive license to import, offer for sale and sell Licensed Products in the Collaborative Fields in the U.S. Territory, and (iv) an exclusive license to make Licensed Products in the Collaborative Fields in the Territory.
License Property
Licensed Product shall mean any pharmaceutical product having as an active ingredient Daclizumab, but excluding Nutley Dac.  Daclizumab means that certain humanized murine monoclonal antibody directed against the p55 component of IL-2R and given the generic name “Daclizumab” by the United States Adopted Names Council. Daclizumab does not include fragments of such antibody or any antibodies having a different amino acid sequence from such antibody.   IL-2R means the IL-2 receptor.

Licensor Inventions means all inventions that (a) relate to or are useful with antibodies that bind the IL-2 receptor (IL-2R) and (b) are made during the term of this Agreement by employees of Licensor or persons contractually required to assign or license patent rights covering such inventions to Licensor, in the course of performing Licensor’s obligations, or exercising Licensor’s rights, under this Agreement.

Field of Use
Asthma Field means the treatment and/or prevention of asthma or other respiratory diseases.

Transplant Field means the Transplant Indications.

A Collaborative Field (i.e., used in the singular) shall refer either to the Asthma Field (unless and until the Asthma Field is excluded from the definition of Collaborative Field) or the Transplant Field (unless and until the Transplant Field is excluded from· the definition of Collaborative Field.  Collaborative Fields shall be deemed to exclude the field (i.e., Asthma Field or Transplant Field) with respect to which the rights are so terminated.

IPSCIO Record ID: 279903

License Grant
Licensor hereby grants to the Swiss Licensee a co-exclusive license (together with Licensor), under the Licensor Technology, to develop Licensed Products in the Collaborative Fields with respect to the U.S. Territory and the European Union, in accordance with the Asthma Development Plan and Transplant Development Plan, and to import and use Licensed Products for such purposes. The foregoing licenses include the right to perform Development outside the U.S. Territory and European Union in accordance with the Asthma Development Plan and Transplant Development Plan with respect to any Licensed Product, solely in order to obtain Regulatory Approval of such Licensed Product in the Collaborative Fields in the U.S. Territory or the European Union.

Licensor hereby grants to Licensee a co-exclusive (together with Licensor), non-transferable right to Promote and Detail Licensed Products in the Asthma Field in the U.S. Territory, in accordance with applicable law and the Asthma Commercialization Plan.

License Property
Licensed Product shall mean any pharmaceutical product having as an active ingredient Daclizumab, but excluding Nutley Dac.  Daclizumab means that certain humanized murine monoclonal antibody directed against the p55 component of IL-2R and given the generic name “Daclizumab” by the United States Adopted Names Council. Daclizumab does not include fragments of such antibody or any antibodies having a different amino acid sequence from such antibody.  IL-2R means the IL-2 receptor.

Transplant Indications means all indications that involve the suppression of rejection of transplanted organs, bone marrow or other tissue, including, without limitation, solid organ transplantation (including tolerance induction and xenotransplantation), bone marrow transplantation, graft versus host disease and cell transplantation. In any event, if a given indication satisfies the criteria for both an Autoimmune Indication and a Transplant Indication, such indication shall be deemed a Transplant Indication and not an Autoimmune Indication, provided that an Autoimmune Indication shall not be deemed a Transplant Indication merely because it may cause the need for a transplant (e.g., Type I diabetes, even if it causes the need for an organ transplant).

Licensor Technology means Licensor Know-How and Licensor Patents.

Field of Use
Collaborative Field (i.e., used in the singular) shall refer either to the Asthma Field (unless and until the Asthma Field is excluded from the definition of Collaborative Field or the Transplant Field (unless and until the Transplant Field is excluded from· the definition of Collaborative Field.

Asthma Field means the treatment and/or prevention of asthma or other respiratory diseases.

Transplant Field means the Transplant Indications.

IPSCIO Record ID: 279346

License Grant
Licensor grants to the Swiss Licensee a sole and exclusive, even as to Licensor, worldwide right and license under the Licensor Patents and Licensor Know-How to make, have made, use, offer for sale, sell and import Licensed Products in the Field.

Licensor grants a nonexclusive, nontransferable. limited right to use the Licensor trademark.

License Property
Licensor owns or controls patents and know-how related to a series of proprietary compounds which act as purine nucleoside phosphorylase inhibitors (PNP Inhibitors), including the compound known as –X-4208.

Compound means the PNP Inhibitor known as –X-4208.

Field of Use
The Field means the prevention or treatment of Autoimmune Indications and Transplantation Indications.

Autoimmune Indications means all indications that involve pathogenic consequences, including tissue injury, produced by autoantibodies or autoreactive T lymphocytes interacting with self epitopes, i.e., autoantigens.

Transplantation Indications means all indications that involve the suppression of rejection of transplanted organs, bone marrow or other tissue, including, without limitation, solid organ transplantation (including tolerance induction and xenotransplantation), bone marrow transplantation, graft versus host disease and cell transplantation.

BCX-4208 is for the prevention of acute rejection in transplantation and for the treatment of autoimmune diseases.

IPSCIO Record ID: 275845

License Grant
Licensor grants to Swiss Licensee and to Licensee’s Affiliates, during the Commercialization Term, the exclusive (even as to Licensor) right and license under the Licensor Know-How and Licensor Patents to (i) market, promote, and detail Nutley Dac in the Licensee Territory solely for use in Transplant Induction, and (ii) to sell and offer for sale Nutley Dac in the Licensee Territory under the Trademarks. In addition, Licensor grants to Licensee and to Licensee’s Affiliates, the nonexclusive right under the Licensor Know-How and Licensor Patents to make, have made, use and import Nutley Dac, but only to the extent reasonably necessary for Licensee to carry out its rights and obligations under this Second Amended and Restated Worldwide Agreement. Licensee may sublicense the rights and licenses granted to Licensee, subject to Licensor’s written consent, which consent Licensor may not unreasonably withhold. It shall be deemed reasonable for Licensor to withhold consent with respect to sublicense by Licensee of any of the rights or licenses to any other entity that is developing (in at least one Phase II clinical trial with directional human efficacy data), or marketing or selling in a Major Country any product for the treatment of any Autoimmune Indication. Notwithstanding the preceding sentence, Licensee and its Affiliates may use Third Party distributors in accordance with their customary practices. All sublicenses granted by Licensee or its Affiliates of the licenses set forth in this agreement shall automatically terminate at the end of the Commercialization Term.
License Property
Nutley Dac shall mean the FDA-approved form of Daclizumab manufactured at Licensee’s Nutley, New Jersey facility as of the Amendment Effective Date.

Daclizumab shall be deemed to be a Licensed Product, a humanized antibody now known by the generic name daclizumab, which binds to the interleukin-2 receptor (“IL-2R”). Daclizumab means any product that contains humanized anti-Tac (as defined under Field).

Licensor Patent Rights
Patent No. 5,585,089, “Humanized Immunoglobulins,” issued December 17, 1996.
Patent No. 5,693,761, “Polynucleotides Encoding Improved Humanized Immunoglobulins,” issued December 2, 1997.
Patent No. 5,693,762, “Humanized Immunoglobulins,” issued December 2, 1997.
Patent No. 6,180,370 “Humanized Immunoglobulins and Method of Making the Same”, issued January 30, 2001.

Trademarks means the trademark “Zenapax®,” and all trademark registrations and applications therefor, and all goodwill associated therewith, and all other trademarks owned by Licensee (except for any Licensee housemarks or trade names) and used in connection with the sale or promotion of Nutley Dac in the Licensee Territory.

Licensee Owned Patents means all patent applications owned by Licensee or its Affiliates (“Sole Licensee Patents”) alone or with a Third Party, and all patent applications resulting from Joint Inventions (“Joint Licensee-Licensor Patents”) covering inventions in the Field that are filed prior to or during the term of this Second Amended and Restated Worldwide Agreement in the United States or any foreign jurisdiction, including any addition, continuation, continuation-in-part or division thereof or any substitute application therefor; any patent issued with respect to such patent application, any reissue, extension or patent term extension of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent; and any other United States or foreign patent or inventor’s certificate covering inventions in the Field. Licensee Owned Patents as of the Effective Date are, specifically, those listed.
Serial No. 60/416,302 – Use of IL-2 Receptor Antibodies

Joint Inventions means any inventions in the Field, whether patented or not, that are jointly made during the period beginning on January 31, 1989 and continuing until the end of the Commercialization Term by at least one (1) Licensor employee or person contractually required to assign or license patent rights covering such inventions to Licensor and at least one (1) Licensee-Nutley or Licensee employee or person contractually required to assign or license patent rights covering such inventions to Licensee-Nutley or Licensee.

Field of Use
Field means any humanized or chimeric antibody that binds to IL-2R, where “humanized” means a genetically engineered combination of a substantially human framework region and constant region, and complementarity determining regions from non-human antibodies, and where “chimeric” means a genetically engineered combination of human constant region and non-human variable region. “Antibodies in the Field” means humanized and chimeric antibodies that bind to IL-2R. It is believed that these Antibodies in the Field may be useful for therapeutic, diagnostic, imaging and similar purposes. It is understood that the Field includes, but is not limited to, that certain humanized murine monoclonal antibody prepared against the p55 component of IL-2R (“humanized anti-Tac”). Furthermore, the Field includes, but is not limited to, all improvements relating to humanized anti-Tac, including without limitation modifications in structure introduced by genetic engineering, or by chemical or enzymatic cleavage. Also included within the Field shall be alternate hosts for producing humanized anti-Tac, methods for purification, formulations incorporating humanized anti-Tac, and uses and methods of use for humanized anti-Tac in human medicine.

Daclizumab is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis.

IPSCIO Record ID: 310351

License Grant
Swiss Seller grants to Purchaser an exclusive, perpetual, irrevocable, royalty-bearing, sublicensable, assignable license under the Licensed IP to use the Licensed IP solely to Develop and Commercialize the Product in the Field in the Territory and to manufacture or have manufactured the Product for use in the Field in the Territory.
License Property
Product means (i) Synacthen and Synacthen Depot, and (ii) any product for use in the Field in the Territory containing the Drug Substance (either alone or in combination with other active pharmaceutical ingredients) which is Developed or Commercialized using the Licensed IP. For the sake of clarity, the Parties acknowledge and agree that the Product does not include the tetracosactide product commercialized by Sellers Affiliate as of the Effective Date.

Synacthen is a synthetic melanocortin agonis for certain autoimmune and inflammatory conditions.  The Synacthen transaction leverages our understanding of the different characteristics and biological activity of melanocortin receptor agonists as well as the potential use of melanocortin receptor agonists in the treatment of serious and difficult-to-treat autoimmune and inflammatory disorders.

Synacthen means SYNACTHEN® i.m./i.v. 0.25 mg/mL solution for injection (or other dosage strength and/or form) that includes the Drug Substance as the sole active ingredient.

Synacthen Depot means SYNACTHEN DEPOT® i.m. 1 mg/mL suspension for injection (or other dosage strength and/or form) that includes the Drug Substance as the sole active ingredient.

Drug Substance means the active pharmaceutical ingredient tetracosactide acetate (a synthetic ACTH analogue) contained in the Product having the structure set forth in this Agreement, and all other salt forms of such tetracosactide.

Trademark means the trademark SYNACTHEN (Serial Number 85495963 with filing date December 15, 2011) in the Territory as provided in this agreement, including all goodwill associated therewith.

Licensed IP means any Global Medical Information, Know How, the Trademark, the Domain Names and Information (and any intellectual property rights in the foregoing) in each case that is necessary for the Development and/or Commercialization of Product in the Field in the Territory and in each case that is in existence and owned or controlled by Seller and/or its Affiliates or which Seller and/or its Affiliates have a right to license as of the Effective Date.

Domain Names shall mean synacthen.com.

Global Medical Information shall mean any medical or clinical information, adverse event reports and/or safety information related to the Product and/or the Drug Substance owned or controlled by or on behalf of Seller and/or its Affiliates in the Field, and including but not limited to clinical study reports, pre-clinical data and toxicity data that are in existence on the Effective Date.

Field of Use
Field shall mean all uses in humans for the treatment of serious and difficult-to-treat autoimmune and inflammatory disorders by leveraging the understanding of the different characteristics and biological activity of melanocortin receptor agonists as well as the potential use of melanocortin receptor agonists in the treatment of these disorders.

Synacthen and Synacthen Depot are available in more than forty countries to treat a number of conditions including some rheumatoid diseases, ulcerative colitis, chronic skin conditions not responsive to corticosteroids, Bell's palsy, acute exacerbations in patients suffering from multiple sclerosis and periarteritis nodosa. Synacthen and Synacthen Depot are also used as a diagnostic test for adrenal insufficiency.

Purchaser is a biopharmaceutical company primarily focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders.

IPSCIO Record ID: 319166

License Grant
Licensor grants the German Licensee a co-exclusive license or sublicense, as applicable, under the  Licensor Technology and Licensors interest in Joint Collaboration Technology to Develop the Product for Commercialization in the Field in the Territory, and, a co-exclusive right under the Licensor Technology, and Licensors interest in Joint Collaboration Technology and the Licensor Manufacturing Know-How to Manufacture the Product in the Field in the Territory, and, an exclusive, royalty-bearing license or sublicense, as applicable, under the Licensor Technology and Licensors interest in Joint Collaboration Technology to Commercialize the Product in the Field in the Territory.

This agreement includes a non-exclusive grant back from Licensee to Licensor.

License Property
Licensor has developed and is currently further developing a pharmaceutical product known as VELTUZUMAB.  VELTUZUMAB means humanized anti-CD20 antibody, also known as IMMU-106 and hA20.

The patent is for Anti-CD20 Antibodies and Fusion Proteins Thereof and Methods of Use.

Field of Use
Field means the treatment, palliation or prevention of non-cancer indications such as autoimmune and inflammatory diseases in humans using the Subcutaneous Formulation of the Product. For purposes of this Agreement, autoimmune and inflammatory diseases include, but are not limited to rheumatoid arthritis, systemic lupus erythematosus, Sj6grens syndrome, vasculitis, colitis, pancreatitis, idiopathic thrombocytopenic purpura, multiple sclerosis, myasthenia gravis, Graves disease and pemphigus vulgaris. For the avoidance of doubt, Field shall not include any oncology indications.

Licensee has significant experience in the development and commercialization of pharmaceutical products in the Territory.

IPSCIO Record ID: 203271

License Grant
To Perform Preclinical Development and Development, Licensor grants to the Japanese Licensee a co-exclusive license in the Territory to use and otherwise exploit subject matter within the Licensor Technology, including the right to use and import Products and Compounds, solely in the Field for the purpose of conducting Preclinical Development and Development activities with respect to Products and Compounds.

To Manufacture Products, Licensor grants a co-exclusive license, whereby Licensor retains the right to Manufacture, including the right to make, have made, and import, Bulk Drug Substance and Finished Drug Product solely for supply to Licensee or for use in Preclinical Development or Development activities as set forth, or for supply to Licensor with respect to activities to be conducted by Licensor pursuant to applicable Plans, or for supply to Licensor.

To Commercialize Products, Licensor grants an exclusive (even as to Licensor) license under the Licensors Technology to Commercialize, including, without limitation, sell, have sold, offer for sale and use in connection therewith, Products and Compounds, in each case solely in the Field in the Territory.  The license granted includes the right to grant sublicenses outside of France, Germany, Italy, Japan, Spain, the United Kingdom or the United States.

For the marks, Licensor grants a non-exclusive license to use the Licensor Mark solely in connection with the marketing, promotion and sale of the Co-Promotion Product(s) in the Field.

License Property
Licensor owns or possesses certain Patents and Know-How with respect to certain CTLA-4 proteins with potential applications in autoimmune and inflammatory disease or as an immunosuppressant.

Licensor Technology means Know-How, Patents, and Licensors rights and interest in all other Alliance Technology. For clarity, the Licensor Technology excludes any Shuffling Technology.

The patents are for Immunosuppressive Polypeptides and Nucleic Acids.

'CTLA-4 Variant'' means (i) any amino acid (including any natural, synthetic, modified or other amino acid analogue) chain that is a Cytotoxic T lymphocyte associated antigen 4 or any variant, homo log, derivative, mutant or fragment thereof ( each, a 'CTLA-4 Molecule') and (ii) any CTLA-4 Molecule that is conjugated or otherwise coupled to any other molecule (e.g., polyethylene glycol, immunoglobulin domain, sialylation, pegylated, or glycosylation).

Field of Use
The Field means the discovery, research, development, manufacture, commercialization or other exploitation of CTLA-4 Variants for Treatment of any and all Indications. Any and all applications not specifically set forth in the preceding sentence are excluded from the Field.

Licensee will receive worldwide rights to commercialize MAXY-4 lead candidates for all autoimmune diseases and transplant rejection. MAXY-4 is Licensor's preclinical program to create a next-generation CTLA4-Ig protein for rheumatoid arthritis, transplant rejection and other autoimmune indications.

IPSCIO Record ID: 329550

License Grant
The Canadian Licensor grants the Japanese Licensee an exclusive, transferable license, with the right to grant sublicenses, under the Licensor Technology, the Product Marks and Licensor’s interest in Joint Technology to
(i)    use, Develop, have Developed, Commercialize and conduct Medical Affairs for the Products in the Field in the Licensee Territory, and
(ii)    Package and have Packaged the Products for use in the Field in the Otsuka Territory.

This agreement includes an exclusive and non-exclusive grant back from Licensee to Licensor.

License Property
Licensor is a biopharmaceutical company, is developing its proprietary investigational drug known as Voclosporin, a proprietary calcineurin inhibitor.

Voclosporin is a novel, investigational, orally administered treatment developed to treat patients with LN, a chronic, progressive inflammation of the kidneys that is one of the most serious complications of the autoimmune disease systemic lupus erythematosus (SLE).

Field of Use
The Field means use of the Product for the treatment and prevention of any and all diseases, conditions and indications in humans.  Voclosporin is known for the treatment of Lupus Nephritis (LN).

Lupus nephritis is inflammation of the kidney that is caused by systemic lupus erythematous (SLE). Also called lupus, SLE is an autoimmune disease. With lupus, the body's immune system targets its own body tissues. Lupus nephritis happens when lupus involves the kidneys.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.